LAL-BR/2001: Study Treatment to Low Risk ALL

NCT00526175 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: Prednisone
DRUG: Vincristine
DRUG: Daunorubicin
DRUG: L-Asparaginase
DRUG: Cyclophosphamide
DRUG: Methotrexate
DRUG: Cytosine Arabinoside
DRUG: Mercaptopurine
DRUG: VP-16

Sponsor

PETHEMA Foundation